参考文献/References:
[1]Song R,Qian H,Wang Y,et al. Research progress on the cardiovascular protective effect of glucagon-like peptide-1 receptor agonists[J]. J Diabetes Res,2022,2022:4554996.
[2]Holst JJ,Orskov C,Nielsen OV,et al. Truncated glucagon-like peptide I,an insulin-releasing hormone from the distal gut[J]. FEBS Lett,1987,211(2):169-174.
[3]Nauck MA,Kleine N,Orskov C,et al. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1(7-36 amide) in type 2(non-insulin-dependent) diabetic patients[J]. Diabetologia,1993,36(8):741-744.
[4]Wettergren A,Schjoldager B, Mortensen PE,et al. Truncated GLP-1(proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man[J]. Dig Dis Sci,1993,38(4):665-673.
[5]Gallo G, Pierelli G ,Forte M,et al. Role of oxidative stress in the process of vascular remodeling following coronary revascularization[J]. Int J Cardiol,2018,268:27-33.
[6]Pyke C ,Heller RS, Kirk RK ,et al. GLP-1 receptor localization in monkey and human tissue:novel distribution revealed with extensively validated monoclonal antibody[J]. Endocrinology,2014,155(4):1280-1290.
[7]Cantini G, Mannucci E, Luconi M. Perspectives in GLP-1 research:new targets,new receptors[J]. Trends Endocrinol Metab,2016,27(6):427-438.
[8]Kalra S, Bhattacharya S, Kapoor N. Contemporary classification of glucagon-like peptide 1 receptor agonists(GLP1RAs)[J]. Diabetes Ther,2021,12(8):2133-2147.
[9]Holman RR, Bethel MA, Mentz RJ,et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes[J]. N Engl J Med,2017,377(13):1228-1239.
[10]VergèsB,Charbonnel B. After the LEADER trial and SUSTAIN-6,how do we explain the cardiovascular benefits of some GLP-1 receptor agonists?[J]. Diabetes Metab,2017,43 suppl 1:2S3-2S12.
[11]Marso SP,Bain SC,Consoli A,et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes[J]. N Engl J Med,2016,375(19):1834-1844.
[12]Gerstein HC,Colhoun HM,Dagenais GR,et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes(REWIND):a double-blind,randomised placebo-controlled trial[J]. Lancet,2019,394(10193):121-130.
[13]Aroda VR, Ratner R. The safety and tolerability of GLP-1 receptor agonists in the treatment of type 2 diabetes:a review[J]. Diabetes Metab Res Rev,2011,27(6):528-542.
[14]Yu HJ, Rimbert A, Palmer AE,et al. GPR146 deficiency protects against hypercholesterolemia and atherosclerosis[J]. Cell,2019,179(6):1276-1288.e14.
[15]Bu?dak ?,Machnik G, Bu?dak RJ,et al. Exenatide and metformin express their anti-inflammatory effects on human monocytes/macrophages by the attenuation of MAPKs and NFκB signaling[J]. Naunyn Schmiedebergs Arch Pharmacol,2016,389(10):1103-1115.
[16]Wang YG, Yang TL. Liraglutide reduces oxidized LDL-induced oxidative stress and fatty degeneration in Raw 264.7 cells involving the AMPK/SREBP1 pathway[J]. J Geriatr Cardiol,2015,12(4):410-416.
[17]Luo XJ, Hu YM, He S,et al. Dulaglutide inhibits high glucose-induced endothelial dysfunction and NLRP3 inflammasome activation[J]. Arch Biochem Biophys,2019,671:203-209.
[18]Chen A, Chen ZW, Xia Y,et al. Liraglutide attenuates NLRP3 inflammasome-dependent pyroptosis via regulating SIRT1/NOX4/ROS pathway in H9c2 cells[J]. Biochem Biophys Res Commun,2018,499(2):267-272.
[19]Yu XY, Hao M, Liu Y,et al. Liraglutide ameliorates non-alcoholic steatohepatitis by inhibiting NLRP3 inflammasome and pyroptosis activation via mitophagy[J]. Eur J Pharmacol,2019,864:172715.
[20]Xia JG, Li QX, Liu YY,et al. A GLP-1 analog liraglutide reduces intimal hyperplasia after coronary stent implantation via regulation of glycemic variability and NLRP3 inflammasome/IL-10 signaling in diabetic swine[J]. Front Pharmacol,2020,11:372.
[21]Athauda D, Foltynie T. Protective effects of the GLP-1 mimetic exendin-4 in Parkinson’s disease[J]. Neuropharmacology,2018,136(Pt B):260-270.
[22]Bruen R, Curley S, Kajani S,et al. Liraglutide attenuates preestablished atherosclerosis in apolipoprotein E–deficient mice via regulation of immune cell phenotypes and proinflammatory mediators[J]. J Pharmacol Exp Ther,2019,370(3):447-458.
[23]He JS, Kang YY, Lian CW,et al. Effect of miR-19b on the protective effect of Exendin-4 on islet cells in non-obese diabetic mice[J]. Exp Ther Med,2019,18(1):503-508.
[24]Huang JW, Yi HH, Zhao CL,et al. Glucagon-like peptide-1 receptor(GLP-1R) signaling ameliorates dysfunctional immunity in COPD patients[J]. Int J Chron Obstruct Pulmon Dis,2018,13:3191-3202.
[25]Fu ZH, Mui D, Zhu H,et al. Exenatide inhibits NF-κB and attenuates ER stress in diabetic cardiomyocyte models[J]. Aging(Albany NY),2020,12(9):8640-8651.
[26]Chen JJ, Xu SN, Zhou W,et al. Exendin-4 reduces ventricular arrhythmia activity and calcium sparks-mediated sarcoplasmic reticulum Ca leak in rats with heart failure[J]. Int Heart J,2020,61(1):145-152.
[27]Bai XJ, Hao JT, Zheng RH,et al. Glucagon-like peptide-1 analog liraglutide attenuates pressure-overload induced cardiac hypertrophy and apoptosis through activating ATP sensitive potassium channels[J]. Cardiovasc Drugs Ther,2021,35(1):87-101.
[28]Chen P, Yang F, Wang WY,et al. Liraglutide attenuates myocardial fibrosis via inhibition of AT1R-mediated ROS production in hypertensive mice[J]. J Cardiovasc Pharmacol Ther,2021,26(2):179-188.
[29]Wang XW, Zhang FX, Yang F,et al. Effects of linagliptin and liraglutide on glucose- and angiotensin Ⅱ-induced collagen formation and cytoskeleton degradation in cardiac fibroblasts in vitro[J]. Acta Pharmacol Sin,2016,37(10):1349-1358.
[30]Koshibu M, Mori Y, Saito T,et al. Antiatherogenic effects of liraglutide in hyperglycemic apolipoprotein E-null mice via AMP-activated protein kinase-independent mechanisms[J]. Am J Physiol Endocrinol Metab,2019,316(5):E895-E907.
[31]Rakipovski G, Rolin B, N?hr J,et al. The GLP-1 analogs liraglutide and semaglutide reduce atherosclerosis in ApoE-/- and LDLr-/- mice by a mechanism that includes inflammatory pathways[J]. JACC Basic Transl Sci,2018,3(6):844-857.
[32]Anholm C, Kumarathurai P, Pedersen LR,et al. Liraglutide in combination with metformin may improve the atherogenic lipid profile and decrease C-reactive protein level in statin treated obese patients with coronary artery disease and newly diagnosed type 2 diabetes:a randomized trial[J]. Atherosclerosis,2019,288:60-66.
[33]Liu Y, Jiang X, Chen X. Liraglutide and metformin alone or combined therapy for type 2 diabetes patients complicated with coronary artery disease[J]. Lipids Health Dis,2017,16(1):227.
[34] Baggio LL, Yusta B, Mulvihill EE,et al. GLP-1 receptor expression within the human heart[J]. Endocrinology,2018,159(4):1570-1584.
[35]Chen JJ, Wang DD, Wang FG,et al. Exendin-4 inhibits structural remodeling and improves Ca 2+ homeostasis in rats with heart failure via the GLP-1 receptor through the eNOS/cGMP/PKG pathway[J]. Peptides,2017,90:69-77.
[36]Darwesh AM, El-Azab MF, Abo-Gresha NM,et al. Cardioprotective mechanisms of exenatide in isoprenaline-induced myocardial infarction:novel effects on myocardial α-estrogen receptor expression and IGF-1/IGF-2 system[J]. J Cardiovasc Pharmacol,2018,71(3):160-173.
[37]Sassoon DJ, Tune JD, Mather KJ,et al. Glucagon-like peptide 1 receptor activation augments cardiac output and improves cardiac efficiency in obese swine after myocardial infarction[J]. Diabetes,2017,66(8):2230-2240.
[38]Shaman AM, Bain SC, Bakris GL,et al. Effect of the glucagon-like peptide-1 receptor agonists semaglutide and liraglutide on kidney outcomes in patients with type 2 diabetes:pooled analysis of SUSTAIN 6 and LEADER[J]. Circulation,2022,145(8):575-585.
[39]Lingvay I, Catarig AM, Frias JP,et al. Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes(SUSTAIN 8):a double-blind,phase 3b,randomised controlled trial[J]. Lancet Diabetes Endocrinol,2019,7(11):834-844.
[40]Nuamnaichati N, Mangmool S, Chattipakorn N,et al. Stimulation of GLP-1 receptor inhibits methylglyoxal-induced mitochondrial dysfunctions in H9c2 cardiomyoblasts:potential role of Epac/PI3K/Akt pathway[J]. Front Pharmacol,2020,11:805.